Journals / MN Oftalmoloji / 2013 / Cilt: 20 - Sayı: 4

The comparison of the effectiveness of combined therapy and monotherapy in the treatment of bacterial keratitis

Bakteriyel keratitlerde kombine tedavi ve monoterapinin etkinliğinin karşılaştırılması

Pages
232–239
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The advantage of fourth generation fluoroquinolones was the lesser extent of drug side effects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The purpose of this study was to evaluate the effects of combined treatment and monotherapy in bacterial keratitis patients.
📊
Key Findings & Data:Material and Method: The records of 83 patients with bacterial keratitis were evaluated retrospectively and patients were divided into two groups: Group 1 (n=41) and Group 2.
💡
Conclusion & Impact:The advantage of fourth generation fluoroquinolones was the lesser extent of drug side effects.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: The purpose of this study was to evaluate the effects of combined treatment and monotherapy in bacterial keratitis patients. Material and Method: The records of 83 patients with bacterial keratitis were evaluated retrospectively and patients were divided into two groups: Group 1 (n=41) and Group 2. Group 1 was comprised of patients who were treated with a 5% cefazolin and 1.3% gentam- icin combination. The Group 2 patients were treated with gatifloxacin (n=26) or moxifloxacin (n=16) monotherapy. Results: The groups were similar regarding the gender (p=0.938), mean age (p=0.492), mean follow-up time (p=0.509), initial mean visual acuity (0.05), ulcer diameter (p=0.690), ulcer localization (p=0.993), ulcer depth (p=0.822), anterior chamber reaction (p=0.741) and hypopyon (p=0.746). The mean epithelization time was 11.9±4.78 in Group 1 and 13.26±4.88 in Group 2 (p=0.211). At the last visit, the mean visual acuity was 0.351±0.346 in Group 1 and 0.486±0.418 in Group 2 (p=0.235). The side effects were observed more frequently in Group 1 than in Group 2 (p=0.037). Conclusion: The same outcomes were achieved when bacterial keratitis patients were treated with a cefazolin/gentamicin combination or with gatifloxacin or moxifloxacin monotherapy. The advantage of fourth generation fluoroquinolones was the lesser extent of drug side effects.

Özet

Amaç: Kombine tedavi veya monoterapi ile tedavi ettiğimiz bakteriyel keratitli olgularımı- zın sonuçlarını karşılaştırmayı amaçladık. Gereç ve Yöntem: Çalışma kriterlerine uyan 83 bakteriyel keratitli hastanın (83 göz) dos- yası retrospektif olarak incelendi ve olgular iki gruba ayrıldı. Grup 1 (n=41) ve Grup 2 (n=42). Grup 1’e %5 sefazolin ve %1,3 gentamisin kombinasyonu ile tedavi edilen olgular alındı. Grup 2 hastaları gatifloksasin (n=26) veya moksifloksasin (n=16) ile monoterapi uy- gulananlardı. Bulgular: Gruplar cinsiyet (p=0,938), yaş ortalaması (p=0,492), ortalama takip süresi (p=0,509), başlangıç görme keskinliği (0,05), ülser genişliği (p=0,690), ülser yerleşimi (p=0,993), ülser derinliği (p=0,822), ön kamara reaksiyonu (p=0,741) ve hipopiyon (p=0,746) bakımından benzerdi. Ülserin üzerindeki epitelin ortalama iyileşme süresi Grup 1’de 11,9±4,78 gün ve Grup 2’de 13,26±4,88 gündü (p=0,211). Tedavi sonrası ortalama gör- me keskinliği Grup 1’de 0,351±0,346 ve Grup 2’de 0,486±0,418 olarak bulundu (p=0,235). Grup 1’de 24 (%58,5) gözde, Grup 2’de 21 (%50,0) gözde kültürler pozitifti (p=0,435). Kültürde en sık üretilen bakteri Staphylococcus aureus idi (n=12, %14,4). Grup 1’de Grup 2’ye oranla daha sık yan etki ortaya çıktı (p=0,037). Sonuç: Bakteriyel keratitler dördüncü kuşak florokinolonlarla tedavi edildiğinde sefazolin ve gentamisin kombinasyonu ile tedavi edilenlerle benzer sonuçlar elde edilmektedir. Dördüncü kuşak florokinolonların avantajı, kombine tedaviye göre daha seyrek yan etkiye yol açmalarıdır.

🔖

Cite This Article

ABAY, İ., YALNIZ, Z. A., BURCU, A., YILDIZ, H. E., ÖZKAN, G. Ü., ÖRNEK, F. (2013). The comparison of the effectiveness of combined therapy and monotherapy in the treatment of bacterial keratitis. MN Oftalmoloji, Cilt: 20 - Sayı: 4, 232–239. https://ajindex.com/articles/295705

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Schaefer F, Bruttin O, Zografos L, Guex-Crosier Y. Bacterial keratitis: a prospective clinical and microbiological study. Br J Ophthalmol 2001;85:842-7
  2. Constantinou M, Daniell M, Snibson GR, Vu HT, Taylor HR. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. Ophthalmology 2007; 114:1622-9
  3. Price MO, Price FW, Jr., Maclellan D. Effect of gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions on human corneal epithelium following 2 dosing regimens. J Cataract Refract Surg 2005;31:2137-41
  4. Price MO, Quillin C, Price FW, Jr. Effect of gatifloxacin oph- thalmic solution 0.3% on human corneal endothelial cell den- sity and aqueous humor gatifloxacin concentration. Curr Eye Res 2005;30:563-7
  5. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4- quinolones. Microbiol Mol Biol Rev 1997;61:377-92
  6. Asbell PA, Colby KA, Deng S, McDonnell P, Meisler DM, Raizman MB, et al. Ocular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolates. Am J Ophthalmol 2008;145:951-8
  7. Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004;30:287-90
  8. Shah VM, Tandon R, Satpathy G, Nayak N, Chawla B, Agarwal T, et al. Randomized clinical study for comparative evaluation of fourth-generation fluoroquinolones with the combination of fortified antibiotics in the treatment of bacter- ial corneal ulcers. Cornea 2010;29:751-7
  9. Panda A, Ahuja R, Sastry SS. Comparison of topical 0.3% ofloxacin with fortified tobramycin plus cefazolin in the treat- ment of bacterial keratitis. Eye (Lond) 1999;13:744-7
  10. Matthews TD, Frazer DG, Minassian DC, Radford CF, Dart JK. Risks of keratitis and patterns of use with disposable con- tact lenses. Arch Ophthalmol 1992;110:1559-62
  11. Stapleton F, Keay L, Edwards K, Holden B. The Epidemiology of Microbial Keratitis With Silicone Hydrogel Contact Lenses. Eye Contact Lens 2012 [Epub ahead of print] 12. Willcox MD. Management and treatment of contact lens-re- lated Pseudomonas keratitis. Clin Ophthalmol 2012;6:919-24
  12. Daniell M, Mills R, Morlet N. Microbial keratitis: what's the pre- ferred initial therapy? Br J Ophthalmol 2003;87:1167
  13. Bourcier T, Thomas F, Borderie V, Chaumeil C, Laroche L. Bacterial keratitis: predisposing factors, clinical and microbio- logical review of 300 cases. Br J Ophthalmol 2003;87:834-8
  14. Prokosch V, Gatzioufas Z, Thanos S, Stupp T. Microbiological findings and predisposing risk factors in corneal